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Background: Sepsis has been identified as the most common cause of acute kidney injury (AKI) in intensive care
units. Lipopolysaccharide (LPS) induces the production of several proinflammatory cytokines including tumor
necrosis factor (TNF)-alpha, a major pathogenetic factor in septic AKI. c-Fos/activator protein (AP)-1 controls the
expression of these cytokines by binding directly to AP-1 motifs in the cytokine promoter regions. T-5224 is a new
drug developed by computer-aided drug design that selectively inhibits c-Fos/AP-1 binding to DNA. In this study,
we tested whether T-5224 has a potential inhibitory effect against LPS-induced AKI, by suppressing the TNF-alpha
inflammatory response and other downstream effectors.
Methods: To test this hypothesis, male C57BL/6 mice at 7 weeks old were divided into three groups (control, LPS
and T-5224 groups). Mice in the control group received saline intraperitoneally and polyvinylpyrrolidone solution
orally. Mice in the LPS group were injected intraperitoneally with a 6 mg/kg dose of LPS and were given
polyvinylpyrrolidone solution immediately after LPS injection. In the T-5224 group, mice were administered T-5224
orally at a dose of 300 mg/kg immediately after LPS injection. Serum concentrations of TNF-alpha, interleukin (IL)-
1beta, IL-6 and IL-10 were measured by ELISA. Moreover, the expression of intercellular adhesion molecule (ICAM)-1
mRNA in kidney was examined by quantitative real-time RT-PCR. Finally, we evaluated renal histological changes.
Results: LPS injection induced high serum levels of TNF-alpha, IL-1beta and IL-6. However, the administration of
T-5224 inhibited the LPS-induced increase in these cytokine levels. The serum levels of IL-10 in the LPS group and
T-5224 group were markedly elevated compared with the control group. T-5224 also inhibited LPS-induced ICAM-1
mRNA expression. Furthermore histological studies supported an anti-inflammatory role of T-5224.
Conclusions: In endotoxin-induced AKI, T-5224 inhibited the production of TNF-alpha and other downstream
effectors. In contrast, T-5224 did not inhibit IL-10, an anti-inflammatory cytokine. These data support that the use of
T-5224 is a promising new treatment for septic kidney injury.
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Recently, the incidence of acute kidney injury (AKI) has
increased considerably. AKI occurs in 19–51% of pa-
tients with sepsis or septic shock, while sepsis is a con-
tributing factor in approximately half of patients with
severe AKI [1]. Although medical practice has advanced
in the last decade, the pathophysiology of sepsis-induced* Correspondence: hiromm78@gmail.com
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reproduction in any medium, provided the orAKI is incompletely understood, and the mortality rate
remains high. Current treatments for sepsis-induced AKI
including intensive insulin therapy and early goal-directed
therapy have been reported to be beneficial; however,
there are still no radical treatments to completely treat
septic AKI [1].
Several inflammatory mediators have been assigned
a key role in sepsis. In response to lipopolysaccharide
(LPS), macrophages and other cells express and release
multiple proinflammatory cytokines, such as tumor ne-
crosis factor (TNF)-α [2]. Although these molecules arel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Miyazaki et al. BMC Nephrology 2012, 13:153 Page 2 of 7
http://www.biomedcentral.com/1471-2369/13/153crucial for host defense against invading bacteria, exces-
sive production of these mediators can result in a lethal
systemic inflammatory response syndrome, which leads
to shock, vascular dysfunction, disseminated intravascu-
lar coagulation and multiple organ dysfunction/injury
[3]. Specifically, the role of TNF-α has been shown to be
critical in the inflammatory response in endotoxemia-
related AKI [3].
The responses to LPS are mostly dependent on the
mitogen-activated protein kinase (MAPK) pathways and
activation of MAPK by dual phosphorylation can en-
hance the transcriptional activity of activator protein
(AP)-1 [4]. The transcription factor, c-Fos/AP-1, directly
controls the expression of inflammatory cytokines, such
as TNF-α, interleukin (IL)-1β and IL-6, by binding di-
rectly to AP-1 motifs in the promoter region of these
genes. Aikawa et al [5]. designed and synthesized a se-
lective inhibitor of c-Fos/AP-1, termed T-5224, using
three-dimensional (3D) pharmacophore modeling based
on a crystal structure of the AP-1–DNA complex, and
found that selective inhibition of c-Fos/AP-1 resolved di-
sease in a mouse model of arthritis. Inhibition of matrix-
degrading matrix metalloproteinases (MMPs) is essential
for effective disease-modifying anti-rheumatic drugs. T-
5224 inhibited the transactivation of matrix-degrading
MMPs via a promoter AP-1 binding motif and protected
the joints in a mouse model of rheumatoid arthritis.
Moreover, T-5224 decreased levels of TNF-α and effi-
ciently protected mice from arthritic joint destruction.
In the present study, we investigated whether T-5224
has an inhibitory effect on LPS-induced AKI in mice by
suppressing the inflammatory response, including TNF-
α and other downstream effectors. Furthermore, as LPS
administration can trigger an influx of neutrophils into
organs such as the kidney, a process directed by the
local expression of adhesion molecules on endothelium,
we tested the effect of T-5224 on intercellular adhesion
molecule (ICAM)-1 expression in the injured kidney.
Methods
Animals
This study was approved by the Institutional Animal
Care and Use Committee and performed according to
the Kobe University Animal Experimental Regulation
(Kobe, Japan). Male C57BL/6 mice (CLEA Japan, Inc.,
Tokyo, Japan) aged 7 weeks were used throughout the
study. They were maintained on standard rodent chow
and allowed free access to water.
Reagents
LPS (Escherichia coli 0111:B4) was purchased from
Sigma-Aldrich Co. (St. Louis, MO,USA).T-5224, 3-{5-[4-
(Cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-
benzisoxazol-6-yl) methoxy]phenyl} propionic acid, wassynthesized and kindly supplied by Toyama Chemical
Co., Ltd (Toyama, Japan) [5]. T-5224 is insoluble in
water; therefore this reagent was dissolved in a poly-
vinylpyrrolidone solution, and adjusted to a concentra-
tion of 30 mg/ml.
Animal protocols, blood chemistry and measurement of
serum cytokine levels
First we examined the peak of serum TNF-α levels after
intraperitoneal administration a 6 mg/kg dose of LPS
(1.25 mg/ml) [6] using a commercially available enzyme-
linked immunosorbent assay (ELISA) kit (R&D systems,
Inc., Minneapolis, MN, USA). For the preparation of se-
rum, mice were anesthetized with an intraperitoneal in-
jection of sodium pentobarbital (Dainippon Sumitomo
Pharma Co., Ltd., Osaka, Japan) and blood samples were
collected from mice via the femoral artery. One-milliliter
aliquots of blood samples were centrifuged (6,700 × g
for 3 min) and then supernatants were stored as serum
at −80°C until used for analysis.
To evaluate the effect of T-5224 on LPS-induced AKI,
mice were assigned to one of three groups (control group,
LPS group and T-5224 group). Mice in LPS group were
administered orally with polyvinylpyrrolidone solution in
the same volume of T-5224 solution immediately after
LPS injection, while in the T-5224 group mice were ad-
ministered orally with T-5224 (300 mg/kg) in the same
manner. In the control group, mice received polyvinylpyr-
rolidone solution orally soon after intraperitoneal saline
injection. Blood samples were collected for each measure-
ment at the optimal time. Serum samples from all groups
were sent to a commercial laboratory service (Special
Reference Laboratories, Tokyo, Japan) to measure serum
blood urea nitrogen (BUN) levels. Serum creatinine (Cr)
concentrations were also examined by enzymatic method
in their laboratory. Serum IL-1β, IL-6 and IL-10 were
measured using ELISA. ELISA kits were purchased from
R&D Systems, Inc. for IL-1β and IL-6 measurements and
Life Technologies (Grand Island, NY, USA) for IL-10 and
were used according to the manufacturer's protocols.
Real-time PCR for ICAM-1 expression
Quantitative real-time PCR was performed to examine
ICAM-1 mRNA expression in LPS-induced AKI. The
kidney was removed at 6 h after LPS or saline injection
[6]. Total RNA from kidney was isolated using Trizol rea-
gent (Life Technologies), according to the manufacturer's
protocol. First strand cDNA was synthesized from 5 μg
total RNA, using random hexamers with PrimeScript
(Takara Bio Inc., Otsu, Japan). Real-time RT-PCR was
performed on StepOnePlus (Life Technologies) using
TaqMan Universal PCR Master Mix (Life Technologies)
and TaqMan gene expression assays (Life Technologies)
for ICAM-1 (assay ID: Mm00516023_m1) and β-actin
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of mRNA expression of the respective genes, according to
the manufacturer's protocol. ICAM-1 levels were normal-
ized by those of β-actin. Data were shown as the quantity
relative to the control group.
Histology
For histopathological observation, the mice were sacri-
ficed and kidneys were removed at 48 h after LPS injec-
tion. Each tissue was fixed in 10% formalin, embedded
in paraffin, sectioned, and then stained with hematoxylin
and eosin for morphological examination.
Statistical analysis
All data were expressed as mean ± standard deviation
(SD). The Kruskal–Wallis test was used to test for over-
all group differences and the Steel-Dwass test was used
to test for between-group differences. Values of P<0.05
were considered to represent statistical significance.
Results
In this study, no mice in LPS group and T-5224 group
died at 48 h after intraperitoneal administration of LPS
with 6 mg/kg.
T-5224 dose-dependently inhibits LPS-induced serum
TNF-α
Serum TNF-α levels in mice peaked at 2 h after LPS in-
jection (Figure 1a). Therefore, we examined the serum
TNF-α levels at this point in all further experiments. Next,
we investigated the dose-dependent effects of T-5224 on
TNF-α expression in endotoxin-induced AKI. All doses
of T-5224 significantly inhibited serum TNF-α levels com-































Figure 1 T-5224 attenuates LPS-induced TNF-α. a, determination of the
on TNF-α at 2 h after intraperitoneal LPS injection. Serum TNF-α levels peak
LPS-induced TNF-α release dose-dependently (n = 7–8 per group). **P < 0.T-5224 inhibited TNF-α dose dependently, as a dose
of 300 mg/kg was more effective in reducing TNF-α
production than that of 30 or 100 mg/kg (Figure 1b).T-5224 reduced serum BUN and Cr and pro-inflammatory
cytokines
Blood samples were collected for the measurement of
serum BUN, Cr, IL-1β, IL-6 and IL-10 at the various op-
timal times (Figure 2). We examined serum BUN and Cr
levels to evaluate kidney function. At the time of LPS or
saline injection, serum BUN and Cr levels were compa-
rable in all groups (Figure 3). In the LPS group, however,
serum BUN and Cr levels were significantly increased at
24 h after LPS injection and further increased at 48 h,
signifying kidney damage, while in the control group
serum BUN and Cr levels remained low. The adminis-
tration of T-5224 reduced serum BUN and Cr levels at
both 24 h and 48 h. For a better understanding of poten-
tial mechanisms whereby T-5224 exerted a protective ef-
fect on renal function, we also analyzed the levels of
serum TNF-α and other downstream cytokines. Serum
TNF-α levels in the LPS group were significantly higher
than in the control group, while treatment with T-5224
significantly attenuated its expression dose-dependently
(Figure 1b). LPS also induced a significant increase in
serum IL-1β and IL-6 levels compared with the con-
trol group. In contrast, T-5224 treatment inhibited LPS-
induced increases of these cytokines (Figure 4a, b).
We also examined the expression of IL-10, an anti-
inflammatory cytokine, and found that stimulation with
LPS resulted in an equally significant up-regulation of













point for TNF-α measurement. b, dose-dependent effects of T-5224
ed after LPS injection at 2 h (1583.8 ± 161.5 pg/ml). T-5224 attenuated
01 vs. control group. #P < 0.05 vs. LPS group. ##P < 0.01 vs. LPS group.






LPS or saline injection
Figure 2 Time course for blood collection. LPS or saline was injected to mice at 0 h. Subsequently, blood was taken at different time points
for the measurement of BUN, Cr, IL-10, IL-6 and IL-1β.
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To determine whether T-5224 was capable of inhibiting
the infiltration of neutrophils into the injured kidney, we
measured mRNA expression of ICAM-1 by quantitative
real-time RT-PCR (Figure 5). Following LPS challenge,
ICAM-1 mRNA levels in the kidney were significantly
higher than in the control group. However, T-5224 signifi-
cantly inhibited LPS-induced ICAM-1 mRNA expression.
T-5224 attenuated LPS-induced histopathological changes
in kidney
To evaluate histopathological characteristics of kidney in
mice, the tissue sections stained with hematoxylin and
eosin were made (Figure 6). After LPS injection, histo-
pathological examination revealed kidney damage cha-
racterized by renal tubular degeneration and dilatation
with variable flattening of the cytoplasm and loss of brush
border. In contrast, treatment with T-5224 reduced the






















Figure 3 Effect of T-5224 on serum BUN and Cr levels after LPS inject
group was significantly lower than that in the LPS group at both 24 h and
mg/dl vs. 180.7 ± 37.4 mg/dl). b, T-5224 also attenuated the increase of se
mg/dl; 48 h, 0.32 ± 0.23 mg/dl vs. 0.93 ± 0.11 mg/dl) (n = 6–12 per group)
LPS group. ##P < 0.01 vs. LPS group.Discussion
In the present study, we demonstrated that a selective
c-Fos/AP-1 inhibitor, T-5224, suppressed LPS-induced
TNF-α production dose-dependently. The inhibition of
TNF-α is considered an effective treatment for septic
AKI. The current study indicates that renal protection
induced by T-5224 administration during endotoxemia
occurs by controlling the expression of TNF-α and other
downstream mediators.
Sepsis has been identified as the most common cause
of AKI in intensive care units. Moreover, the combi-
nation of sepsis and AKI is associated with a very high
mortality rate [1]. There is, therefore, an urgent need to
identify novel therapeutic interventions with the poten-
tial to attenuate septic AKI. Numerous cytokines released
from leukocytes and renal tubular cells in the injured kid-
ney function as essential components of the initiation and
extension of inflammation in AKI [7]. Hence, the pharma-


















ion. LPS induced serum BUN and Cr levels. a, BUN in the T-5224
48 h (24 h, 65.5 ± 13.8 mg/dl vs. 100 ± 15.5 mg/dl; 48 h, 79.8 ± 41.9
rum Cr induced in LPS group (24 h, 0.13 ± 0.04 mg/dl vs. 0.21 ± 0.10
























































Figure 4 Effect of T-5224 on serum cytokines following LPS administration. a, the administration of T-5224 decreased serum IL-1β
(132.7 ± 32.3 pg/ml vs. 335.5 ± 85.9 pg/ml). b, IL-6 levels were decreased after T-5224 treatment (44.4 ± 16.6 ng/ml vs. 113.4 ± 29.1 ng/ml)
as compared with the LPS group. c, serum IL-10 levels in the T-5224 group were similar to the LPS group (1637.7 ± 402.3 pg/ml vs. 1597.7








































Figure 5 Effect of T-5224 on ICAM-1 mRNA expression in
injured kidney. Bars represent the relative ratio of ICAM-1 mRNA to
the control group. T-5224 significantly inhibited LPS-induced ICAM-1
mRNA expression in the kidney (4.2 ± 1.4 vs. 8.2 ± 1.4) (n = 4–6 per
group). **P < 0.01 vs. control group. ##P < 0.01 vs. LPS group.
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xemia with bacterial infection. Recent studies indicated
TNF-α is critical in mediating LPS-induced kidney injury
[8]. Inhibition of TNF-α by genetic or antibody techniques
inhibited renal injury following ischemia [9], cisplatin [10]
or LPS [11] administration.
Aikawa et al. designed and synthesized a selective
c-Fos/AP-1 inhibitor termed T-5224 using 3D pharma-
cophore modeling based on the crystal structure of the
AP-1–DNA complex [5]. c-Fos/AP-1 controls the ex-
pression of inflammatory cytokines including TNF-α by
binding directly to AP-1 motifs in the promoter of the
gene, and T-5224 treatment resolved arthritis in a mouse
model. The transcription factor AP-1 is also activated
by LPS, leading to enhanced TNF-α transcription [12].
T-5224 inhibited the expression of TNF-α and other
cytokines in a mouse arthritis model [5], suggesting it
may also inhibit LPS-induced TNF-α production. In-
deed, we demonstrated that T-5224 attenuated serum
TNF-α levels dose-dependently following LPS adminis-
tration and reduced serum BUN and Cr levels, indica-
ting T-5224 can protect against LPS-induced AKI.
Apart from the inhibition of serum TNF-α during endo-
toxemia, T-5224 decreased other serum cytokines, namely
Figure 6 Renal injury after LPS injection. A, LPS caused tubular injury as manifested by tubular degeneration and dilatation. B, In contrast, there
was less tubular damage in T-5224 group. The sections shown were harvested 48 h after LPS injection and stained with H&E. Magnification: ×400.
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failure and death during endotoxemia. IL-1β, a pro-
inflammatory cytokine, evokes similar pathophysiological
responses to TNF-α. Inhibition of IL-1β signaling by treat-
ment with recombinant IL-1β receptor antagonist, re-
sulted in decreased mortality in an animal model of
endotoxic shock [13]. On the other hand, elevated plasma
concentrations of IL-6 predict AKI in patients with severe
sepsis [14] and mortality in sepsis correlates with the de-
gree of IL-6 up regulation [15]. T-5224 showed a remar-
kable inhibition of IL-1β and IL-6 production in mice
challenged with LPS, suggesting that T-5224 can protect
renal function against LPS, at least in part, via inhibiting
both IL-1β and IL-6 production.
IL-10, an anti-inflammatory cytokine, plays an impor-
tant role in improving survival in animals challenged
with LPS and inhibits several macrophage functions in-
cluding TNF-α production in vivo and in vitro [16].
However, one study has reported that TNF-α signaling
can promote IL-10 production [17]. Considering this,
there was a possibility that T-5224 might inhibit IL-10
production. However, T-5224 did not suppress IL-10
production in our study. This observation is of interest
since modulating the balance between pro-inflammatory
and anti-inflammatory responses and restoring immune
homeostasis of patients is important in the treatment
of sepsis.
The effect of T-5224 on ICAM-1 mRNA expression in
the kidney was also examined. ICAM-1 is a member of
the immunoglobulin-like supergene family of adhesion
molecules known to mediate adherence of polymorph-
onuclear neutrophils (PMNs) to endothelial cells [18].
Both LPS and TNF-α increase the cell surface expression
of ICAM-1 [19], which is one of several downstream
effectors induced by TNF-α. The present study demons-
trated that mRNA expression of ICAM-1 was signifi-
cantly increased in the kidney at 6 h after LPS injection
and was markedly attenuated by treatment of T-5224.
The role of ICAM-1 in PMN accumulation has been sug-
gested in endotoxemic AKI and a deficiency of ICAM-1may confer protection against LPS-induced AKI, by de-
creasing neutrophil adhesion and abrogating signaling
events that occur in endothelium upon ligation of ICAM-
1. Thus, our results suggested that T-5224 might also
protect mice against LPS-induced AKI by decreasing
ICAM-1 expression.
We also examined renal histological change at 48 h
after LPS injection. As previous study reported, LPS
induced severe renal tubular injury [20]. In this study,
mice in LPS group also developed tubular injury. How-
ever, less tubular damage was observed in T-5224 group.
Furthermore, pathological findings were well correlated
with reduced expressions of TNF-α and other down-
stream effectors. These results indicated that T-5224 con-
ferred protection against structural injury caused by LPS.
Interestingly we observed few neutrophils in kidney,
which suggests that ICAM-1 itself may cause renal injury
through other as yet unknown neutrophil-independent
mechanisms.
In the present study, T-5224 did not completely sup-
press all inflammatory mediators. One potential expla-
nation for this could be that genes encoding TNF-α are
also transcriptionally activated through nuclear factor
(NF)-κB activation [21]. NF-κB, a transcription factor, is
critically involved in the regulation of monocytic pro-
duction of pro-inflammatory cytokines, such as TNF-α
and IL-1β. T-5224 specifically inhibits the DNA binding
activity of c-Fos/c-Jun, without affecting that of NF-κB/
p65 [5]. There are also several limitations in our study.
First, we only examined BUN and Cr for kidney func-
tion, although these markers are insensitive and non-
specific for acute changes to kidney function. Therefore,
these biomarkers may not detect an ongoing injury to
the kidney. Second, T-5224 was administrated immedi-
ately after LPS injection. Considering the clinical situ-
ation, the delayed administration of T-5224 should also
be investigated in the future. Third, intravenous admin-
istration is generally more effective than oral administra-
tion. However, we demonstrated that oral treatment with
T-5224 was effective enough to improve kidney injury in
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intravenous drug use is now underway.
Conclusions
We have shown that T-5224 attenuated LPS-induced
AKI in mice. This protection was associated with re-
duced expressions of serum TNF-α and other down-
stream cytokines including IL-1β and IL-6. In addition,
the anti-inflammatory cytokine IL-10 was not affected
by T-5224. Moreover, renal ICAM-1 mRNA induced by
LPS was suppressed by T-5224.
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